TY - JOUR
T1 - Public perceptions of presymptomatic testing for Alzheimer disease
AU - Caselli, Richard J.
AU - Langbaum, Jessica
AU - Marchant, Gary E.
AU - Lindor, Rachel A.
AU - Hunt, Katherine S.
AU - Henslin, Bruce R.
AU - Dueck, Amylou C.
AU - Robert, Jason S.
N1 - Funding Information:
Grant Support: This study was supported by grants P30AG19610 and R01AG031581 from the National Institute on Aging and the Arizona Alzheimer’s Consortium .
Funding Information:
Potential Competing Interests: Dr Caselli receives research funding from Merck.
Publisher Copyright:
© 2014 Mayo Foundation for Medical Education and Research.
PY - 2014/10/1
Y1 - 2014/10/1
N2 - Objective: To explore the self-expressed desire for, envisioned reaction to, and basic understanding of presymptomatic Alzheimer disease (AD)erelated genetic and biomarker tests.Patients and Methods: The Alzheimers Prevention Registry is an online community of people at least 18 years of age who are interested in AD prevention research for purely informational purposes or to be considered for possible research participation in future studies. Information about presymptomatic testing and an online multiple choice format survey were posted from November 1, 2012, through June 20, 2013, on the registry website.Results: Of 4036 respondents, 80.8% (3195/3952) wanted genetic testing if paid by insurance and 58.7% (2261/3851) if it would cost them at least $100. A total of 80.2% (3112/3879) wanted biomarker testing. If at high risk for AD, 90.5% (3478/3841) endorsed that they would "pursue a healthier lifestyle, " but 11.6% (427/3706) endorsed "seriously consider suicide. " The implication of a positive genetic test result was incorrectly understood by 13.1% (500/3812) and 32.6% (1255/3848) failed to view a positive biomarker test result as evidence of increased risk for or the presence of AD.Conclusion: Despite efforts to increase public awareness of AD, our survey results suggest that greater education of the public is needed. Interested patients should probably undergo psychological screening to identify those at high risk of adverse psychological outcomes, and disclosure of presymptomatic test results should be anchored to tangible constructive action plans, such as healthy lifestyle changes, long-term care planning, and, when available and appropriate, participation in research trials.
AB - Objective: To explore the self-expressed desire for, envisioned reaction to, and basic understanding of presymptomatic Alzheimer disease (AD)erelated genetic and biomarker tests.Patients and Methods: The Alzheimers Prevention Registry is an online community of people at least 18 years of age who are interested in AD prevention research for purely informational purposes or to be considered for possible research participation in future studies. Information about presymptomatic testing and an online multiple choice format survey were posted from November 1, 2012, through June 20, 2013, on the registry website.Results: Of 4036 respondents, 80.8% (3195/3952) wanted genetic testing if paid by insurance and 58.7% (2261/3851) if it would cost them at least $100. A total of 80.2% (3112/3879) wanted biomarker testing. If at high risk for AD, 90.5% (3478/3841) endorsed that they would "pursue a healthier lifestyle, " but 11.6% (427/3706) endorsed "seriously consider suicide. " The implication of a positive genetic test result was incorrectly understood by 13.1% (500/3812) and 32.6% (1255/3848) failed to view a positive biomarker test result as evidence of increased risk for or the presence of AD.Conclusion: Despite efforts to increase public awareness of AD, our survey results suggest that greater education of the public is needed. Interested patients should probably undergo psychological screening to identify those at high risk of adverse psychological outcomes, and disclosure of presymptomatic test results should be anchored to tangible constructive action plans, such as healthy lifestyle changes, long-term care planning, and, when available and appropriate, participation in research trials.
UR - http://www.scopus.com/inward/record.url?scp=84908090955&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908090955&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2014.05.016
DO - 10.1016/j.mayocp.2014.05.016
M3 - Article
C2 - 25171823
AN - SCOPUS:84908090955
SN - 0025-6196
VL - 89
SP - 1389
EP - 1396
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 10
ER -